<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384330</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-52120-188</org_study_id>
    <nct_id>NCT02384330</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke</brief_title>
  <acronym>P_Dysport_CS</acronym>
  <official_title>Cost Determination Study For Different Botulinum Toxin A Preparations In The Treatment Of Upper Limb Spasticity Post-Stroke In Portugal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to estimate the costs of botulinum toxin A utilization in standard practice
      for the treatment of upper limb spasticity post-stroke in Portugal.

      It will consider the three most used locally available brands of botulinum toxin A which show
      similar efficacy and safety profiles thus making it relevant to understand if choosing
      between one or another brand can depend directly on economic factors.

      The study will estimate direct and indirect drug-associated costs as determinant variables
      for the price of each drug and the standard drug dose used in clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A comparison will be performed between direct costs associated with each therapeutic strategy
      and cost analysis assuming that quality of life values may be different between patients
      treated with each treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">March 16, 2017</completion_date>
  <primary_completion_date type="Actual">March 16, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the cost of botulinum toxin utilization</measure>
    <time_frame>12 months</time_frame>
    <description>Direct resource utilization and costs of upper limb spasticity patients treated with BoNT-As, by product</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of work days missed due to spasticity</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of Absenteeism /loss of productivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carer time needed for patient assistance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">57</enrollment>
  <condition>Upper Limb Spasticity Post-Stroke</condition>
  <arm_group>
    <arm_group_label>Dysport® (abobotulinumtoxinA)</arm_group_label>
    <description>Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botox® (onabotulinumtoxinA)</arm_group_label>
    <description>Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xeomin® (incobotulinumtoxinA)</arm_group_label>
    <description>Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital ambulatory patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with post-stroke upper limb spasticity

          -  Patients currently being treated with Dysport®, Botox® or Xeomin®

          -  Patients stabilized from a therapeutic point of view - with no switches of treatment
             in at least the 2 last administrations

          -  Patients who gave their written informed consent to participate.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Fillat Boix, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Medicina de Reabilitação de Alcoitão</name>
      <address>
        <city>Alcabideche</city>
        <zip>2649-506</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C. H. A. - Hospital de Faro</name>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C. H. T. M. A. D. - Unidade Hospitalar de Vila Real</name>
      <address>
        <city>Vila Real</city>
        <zip>5000-508</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

